The Food and Drug Administration (FDA) issued a Drug Safety Communication in September 2013 that read, «Boxed warning and new recommendations to decrease risk of hepatitis
B reactivation with the immune - suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab).»
Not exact matches
Individuals previously infected with the hepatitis
B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, «
Reactivation of Hepatitis
B,» and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.
(
B, C) Flow cytometric analysis of HIV - 1 gene expression in (
B) mock infected or (C) latently infected CD4 + T cells under non-polarizing conditions, either at the basal state or after
reactivation with antibodies against CD3 and CD28.